BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 34112709)

  • 1. Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer.
    Byrne KT; Betts CB; Mick R; Sivagnanam S; Bajor DL; Laheru DA; Chiorean EG; O'Hara MH; Liudahl SM; Newcomb C; Alanio C; Ferreira AP; Park BS; Ohtani T; Huffman AP; Väyrynen SA; Dias Costa A; Kaiser JC; Lacroix AM; Redlinger C; Stern M; Nowak JA; Wherry EJ; Cheever MA; Wolpin BM; Furth EE; Jaffee EM; Coussens LM; Vonderheide RH
    Clin Cancer Res; 2021 Aug; 27(16):4574-4586. PubMed ID: 34112709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients.
    Machiels JP; Gomez-Roca C; Michot JM; Zamarin D; Mitchell T; Catala G; Eberst L; Jacob W; Jegg AM; Cannarile MA; Watson C; Babitzki G; Korski K; Klaman I; Teixeira P; Hoves S; Ries C; Meneses-Lorente G; Michielin F; Christen R; Rüttinger D; Weisser M; Delord JP; Cassier P
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33097612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.
    Beatty GL; Chiorean EG; Fishman MP; Saboury B; Teitelbaum UR; Sun W; Huhn RD; Song W; Li D; Sharp LL; Torigian DA; O'Dwyer PJ; Vonderheide RH
    Science; 2011 Mar; 331(6024):1612-6. PubMed ID: 21436454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia.
    Delgado R; Kielbassa K; Ter Burg J; Klein C; Trumpfheller C; de Heer K; Kater AP; Eldering E
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34205588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained Intratumoral Administration of Agonist CD40 Antibody Overcomes Immunosuppressive Tumor Microenvironment in Pancreatic Cancer.
    Liu HC; Davila Gonzalez D; Viswanath DI; Vander Pol RS; Saunders SZ; Di Trani N; Xu Y; Zheng J; Chen SH; Chua CYX; Grattoni A
    Adv Sci (Weinh); 2023 Mar; 10(9):e2206873. PubMed ID: 36658712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic immune response to a CD40 agonist antibody in nonhuman primates.
    Caudell DL; Dugan GO; Babitzki G; Schubert C; Braendli-Baiocco A; Wasserman K; Acona G; Stern M; Passioukov A; Cline JM; Charo J
    J Leukoc Biol; 2024 May; 115(6):1084-1093. PubMed ID: 38372596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD40 Agonist Antibodies in Cancer Immunotherapy.
    Vonderheide RH
    Annu Rev Med; 2020 Jan; 71():47-58. PubMed ID: 31412220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity.
    Morrison AH; Diamond MS; Hay CA; Byrne KT; Vonderheide RH
    Proc Natl Acad Sci U S A; 2020 Apr; 117(14):8022-8031. PubMed ID: 32213589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy.
    Byrne KT; Leisenring NH; Bajor DL; Vonderheide RH
    J Immunol; 2016 Jul; 197(1):179-87. PubMed ID: 27217585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy.
    Farren MR; Sayegh L; Ware MB; Chen HR; Gong J; Liang Y; Krasinskas A; Maithel SK; Zaidi M; Sarmiento JM; Kooby D; Patel P; El-Rayes B; Shaib W; Lesinski GB
    JCI Insight; 2020 Jan; 5(1):. PubMed ID: 31830001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma.
    Beatty GL; Torigian DA; Chiorean EG; Saboury B; Brothers A; Alavi A; Troxel AB; Sun W; Teitelbaum UR; Vonderheide RH; O'Dwyer PJ
    Clin Cancer Res; 2013 Nov; 19(22):6286-95. PubMed ID: 23983255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity.
    Ma HS; Poudel B; Torres ER; Sidhom JW; Robinson TM; Christmas B; Scott B; Cruz K; Woolman S; Wall VZ; Armstrong T; Jaffee EM
    Cancer Immunol Res; 2019 Mar; 7(3):428-442. PubMed ID: 30642833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer.
    Heiduk M; Plesca I; Glück J; Müller L; Digomann D; Reiche C; von Renesse J; Decker R; Kahlert C; Sommer U; Aust DE; Schmitz M; Weitz J; Seifert L; Seifert AM
    JCI Insight; 2022 Nov; 7(22):. PubMed ID: 36509285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan.
    Ei S; Takahashi S; Ogasawara T; Mashiko T; Masuoka Y; Nakagohri T
    Gut Liver; 2023 Sep; 17(5):698-710. PubMed ID: 36843421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agonistic CD40 antibodies and cancer therapy.
    Vonderheide RH; Glennie MJ
    Clin Cancer Res; 2013 Mar; 19(5):1035-43. PubMed ID: 23460534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma.
    Zheng L; Ding D; Edil BH; Judkins C; Durham JN; Thomas DL; Bever KM; Mo G; Solt SE; Hoare JA; Bhattacharya R; Zhu Q; Osipov A; Onner B; Purtell KA; Cai H; Parkinson R; Hacker-Prietz A; Herman JM; Le DT; Azad NS; De Jesus-Acosta AMC; Blair AB; Kim V; Soares KC; Manos L; Cameron JL; Makary MA; Weiss MJ; Schulick RD; He J; Wolfgang CL; Thompson ED; Anders RA; Sugar E; Jaffee EM; Laheru DA
    Clin Cancer Res; 2021 Mar; 27(5):1278-1286. PubMed ID: 33277370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C4b-binding protein α-chain enhances antitumor immunity by facilitating the accumulation of tumor-infiltrating lymphocytes in the tumor microenvironment in pancreatic cancer.
    Sasaki K; Takano S; Tomizawa S; Miyahara Y; Furukawa K; Takayashiki T; Kuboki S; Takada M; Ohtsuka M
    J Exp Clin Cancer Res; 2021 Jun; 40(1):212. PubMed ID: 34167573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model.
    Lau SP; van Montfoort N; Kinderman P; Lukkes M; Klaase L; van Nimwegen M; van Gulijk M; Dumas J; Mustafa DAM; Lievense SLA; Groeneveldt C; Stadhouders R; Li Y; Stubbs A; Marijt KA; Vroman H; van der Burg SH; Aerts J; van Hall T; Dammeijer F; van Eijck CHJ
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harnessing immune responses in the tumor microenvironment: all signals needed.
    Le DT; Jaffee EM
    Clin Cancer Res; 2013 Nov; 19(22):6061-3. PubMed ID: 24097857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.